Africa’s healthcare sector is attracting unprecedented investor interest, and the Corporate Finance team at Nedbank Corporate and Investment Banking (CIB) is at the centre of this trend.
The investment bank recently advised Ethos on the competitive disposal of its investment in Vertice MedTech, a transaction that drew international buyer interest and underscores the growing appeal of healthcare assets in emerging markets.
The transaction forms part of Ethos Fund VI’s ongoing realisation strategy, marking a significant milestone for Ethos and showcasing Nedbank CIB’s advisory capabilities.
Vertice MedTech is a leading independent distributor of specialised medical devices and mobile healthcare solutions.
The company plays a critical role in healthcare delivery across South Africa and other African markets, enabling more than 7 000 surgeries every month and supporting national health programmes through mobile medical units.
Its portfolio spans advanced medical devices, software service and health IT consulting – all of which are essential for improving healthcare access and outcomes in a region where demand for modern medical solutions is rising sharply.
The business also has a growing technological presence in Europe, demonstrating the global nature of modern healthcare companies.
Acting as corporate advisor to both Ethos and Vertice MedTech, Nedbank CIB guided the transaction through a competitive process that attracted strong interest from international buyers.
This outcome reinforces the bank’s ability to execute complex private equity exits and cross-border transactions, particularly in sectors that require deep technical knowledge and strategic insight.
“Healthcare continues to gain momentum as a value-adding investment industry,” says Avinash Kalkapersad, investment banking originator at Nedbank CIB.
“Our involvement in this transaction underscores our ability to deliver strategic outcomes for clients in sectors that matter.”
Michael Jensen, a partner at Ethos, explains: “Having grown Vertice MedTech since its acquisition in 2018, we determined that the timing was right to exit in line with our broader asset realisation strategy.
“Nedbank CIB’s expert advice ensured a successful transaction.”
Michael Jensen, a partner at Ethos. Image: Supplied
The deal comes at a time when healthcare investment across Africa is accelerating, driven by demographic shifts, rising demand for specialised services and the need for technology-enabled solutions.
For investors, the sector offers a compelling combination of financial returns and social impact, making it one of the most attractive areas for capital deployment in emerging markets.
By facilitating the deal, Nedbank CIB has demonstrated its ability to secure global acquirers for strategic African assets – a capability that is increasingly important as cross-border dealmaking becomes more competitive.
The bank has positioned itself to be a key player in the healthcare sector, which continues to grow, driven by ageing populations, technological advancements, a rising prevalence of chronic diseases, and the expansion of the global middle class.
For Nedbank CIB, this transaction is more than a deal. It is a testament to its ability to combine sector expertise with strategic insight, delivering solutions that create value for clients and communities alike.
As healthcare investment accelerates across Africa, Nedbank CIB remains at the forefront, shaping the future of advisory excellence in sectors that matter most.
Healthcare is not just an investment opportunity; it is a sector that directly impacts lives. Transactions such as this enable companies like Vertice MedTech to continue delivering essential services, drive innovation and support health outcomes across Africa.
For investors and stakeholders, these deals represent the intersection of financial performance and social impact – a space in which Nedbank CIB is committed to leading.
Brought to you by Nedbank CIB.
Moneyweb does not endorse any product or service being advertised in sponsored articles on our platform.
#Nedbank #CIB #advises #Ethos #Vertice #MedTech #exit #Amethisled #consortium